As early as October 2024, Nortion Medical had already obtained EU CE Certification and U.S. FDA "Breakthrough Device Designation," completing the compliance reserves for overseas expansion. However, at that time, the company's strategic focus was mainly on China—by the end of 2025, the cumulative number of surgeries exceeded 5,000 cases, with the annual surgical volume increasing by more than 50% compared to 2024.

Westlake Omics' core research and development team has long been dedicated to research in proteomics and virtual cell research, consistently producing top-tier international academic outputs. Most recently, Professor Guo Tiannan's team published two important papers consecutively in the leading international journal Nature.

NewMed, a company deeply engaged in minimally invasive cardiac devices, has previously made three attempts to list on the Hong Kong Stock Exchange. This time, it has chosen to list under the fifth set of listing rules on the STAR Market, planning to raise RMB 1.3 billion to further develop its product pipeline.

Just four months apart, Gestala completed its RMB 420 million Angel+ round of financing. From the Angel round to the Angel+ round, Gestala has raised nearly $100 million in total. Meanwhile, Gestala's Shanghai headquarters has officially commenced operations. According to official information, the Shanghai headquarters primarily undertakes core functions such as the research and development of the AI Brain Foundation Model and international scientific research collaboration, aiming to build a globally leading NeuroAI innovation platform.

Henan Lixinghe Medical Technology Co., Ltd. independently developed a TCM medical device—the acupoint microwave stimulation device—which has passed the full-process review by the NMPA and obtained the Class III Medical Device Registration Certificate, becoming China's first approved Class III TCM medical device. Since 2021, Lixinghe has continuously built a patent matrix around its acupoint microwave stimulation device, establishing a comprehensive portfolio that covers probes, concentrators, complete system integration, and intelligent software. Starting in 2023, Lixinghe initiated its overseas patent strategy, securing international patent families in the United States, the European Union, Japan, and South Korea, and has commenced preparation for FDA and CE certification applications.

TINAVI's acquisition of a controlling stake in Shanghai MicroPort Orthopedics is a typical manifestation of the trend toward industry chain integration. In the future, as competition intensifies, more companies are expected to leverage such integration to optimize their product portfolios and enhance overall competitiveness. This will further increase industry concentration, making the advantages of leading enterprises even more pronounced.

Chinese biotech InnoCare Pharma announced that its next-generation oral TYK2 inhibitor, soficitinib (ICP-332), met the primary endpoint in a Phase II study for adult non-segmental vitiligo. At Week 24, patients receiving 80 mg and 120 mg once-daily doses showed significant improvements in Facial Vitiligo Area Scoring Index (F-VASI) of 38.8% and 41.2% respectively, compared to only 2.2% in the placebo group (P<0.0001). The drug demonstrated a favorable safety profile with no new safety signals observed. InnoCare plans to advance soficitinib into pivotal Phase III trials for vitiligo while also exploring its potential across other T-cell-mediated autoimmune diseases including atopic dermatitis, psoriasis, prurigo nodularis, and urticaria.

Shouyao Holdings (STAR Market: 688197), a Beijing-based biopharmaceutical company, announced on July 16, 2026 that it has received a Clinical Trial Approval Notice from China's National Medical Products Administration (NMPA) for SY-12321 capsules. SY-12321 is a Category 1 innovative drug and a fourth-generation small-molecule ALK inhibitor developed entirely in-house, designed to address drug resistance in anaplastic lymphoma kinase (ALK)-positive advanced solid tumors, particularly resistance driven by ALK compound mutations following third-generation ALK inhibitor treatment. As of the announcement date, SY-12321 is the only fourth-generation ALK inhibitor approved to enter clinical research in China, where no such drug has yet reached the market. The approval marks a significant milestone for the pre-profit company's oncology pipeline, though the drug remains in early-stage clinical testing.

Jiangsu Hengrui Pharmaceuticals announced that its subsidiary Fujian Shengdi Pharma has received approval from China's National Medical Products Administration (NMPA) to initiate a Phase III clinical trial for HRS9531, a novel injectable dual agonist targeting both the GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) for the treatment of obesity combined with knee osteoarthritis in adult patients. Developed with independently owned global intellectual-property rights, HRS9531 has the potential to become a first-in-class therapy, as no drug in the same class has been approved for marketing globally. The company disclosed that cumulative research and development spending on the HRS9531 project has reached approximately 701 million yuan (about US$97 million) to date.

Chengdu Easton Bio Pharmaceuticals Co., Ltd (688513.SH) announced it has received a drug registration certificate from China's National Medical Products Administration (NMPA) for Remimazolam Besylate for Injection, an ultra-short-acting benzodiazepine sedative classified as a Category II psychotropic substance. The drug is approved for sedation and anesthesia during non-tracheal intubation surgical procedures, as well as for the induction and maintenance of general anesthesia. This approval adds a general anesthetic agent to the Shanghai STAR Market-listed company's portfolio of branded generic drugs, addressing growing demand in China's anesthesiology market for shorter-acting sedatives that reduce recovery times and improve patient throughput in outpatient surgical settings.

Westlake Omics' core research and development team has long been dedicated to research in proteomics and virtual cell research, consistently producing top-tier international academic outputs. Most recently, Professor Guo Tiannan's team published two important papers consecutively in the leading international journal Nature.

TINAVI's acquisition of a controlling stake in Shanghai MicroPort Orthopedics is a typical manifestation of the trend toward industry chain integration. In the future, as competition intensifies, more companies are expected to leverage such integration to optimize their product portfolios and enhance overall competitiveness. This will further increase industry concentration, making the advantages of leading enterprises even more pronounced.

VCBeat's analysis reveals that the growth trajectories of these "drug hunters" or entrepreneurial producers are clearly discernible: starting from commercialization and BD roles at large pharmaceutical companies, they transition to become CEOs of biotech firms, successfully creating substantial value for investors in a short period by adopting a model of "acquiring pipelines at low cost, accelerating development, and divesting at high valuations."

From 2025 to 2026, Chinese innovative drugs secured eight of the top ten global licensing deals for two consecutive years. This serves as a testament to the strength of China's innovative pharmaceutical industry as it transitions from "following" and "keeping pace" to "leading the way."

The alliance aims to integrate the technological advantages of Insilico Medicine's proprietary Pharma.AI platform in target discovery, molecule generation, and molecule optimization with Bora Pharmaceuticals' professional capabilities in global drug development, manufacturing, quality management, and commercialization. By bridging the AI-enabled R&D system with automation-driven development, manufacturing, and quality execution processes, both parties are poised to jointly pioneer a new generation of drug R&D models, efficiently integrating the design, development, manufacturing, and delivery of novel molecules, accelerating the provision of innovative solutions for unmet medical needs.

As a Shenzhen-based brain science and brain-inspired intelligence enterprise, Bay Imaging has long focused on the research and development of high-performance brain-dedicated positron emission tomography, small-animal positron emission tomography, and core molecular imaging technologies. The company has established a complete independent research and development system covering positron emission tomography detectors, core electronics, system integration, image reconstruction, and artificial intelligence algorithms.

Just four months apart, Gestala completed its RMB 420 million Angel+ round of financing. From the Angel round to the Angel+ round, Gestala has raised nearly $100 million in total. Meanwhile, Gestala's Shanghai headquarters has officially commenced operations. According to official information, the Shanghai headquarters primarily undertakes core functions such as the research and development of the AI Brain Foundation Model and international scientific research collaboration, aiming to build a globally leading NeuroAI innovation platform.

Centered on the protein immunoblotting workflow, the company has pioneered the globally original contact imaging core technology, overcoming the limitations of traditional cooled charge-coupled device imaging, including signal attenuation, insufficient resolution, and significant quantitative deviations. The technology is compatible with multiple detection modes including chemiluminescence and isotope, and is adaptable to mainstream experimental applications including Western blot, nucleic acid blot, and dot blot.

The uniqueness of HesiMed AI lies in the fact that it is not an isolated large-model product, but rather the core intelligent engine of Hesicare's tripartite system—comprising a chronic disease software platform, a hardware and reagent platform, and data-driven AI—built over many years. Underpinning this is the wealth of real-world data and clinical scenarios accumulated by Hesicare's DMS, which covers more than 3,000 hospitals across China. These long-term accumulations form the foundational capability of HesiMed AI.

Drug Farm has successfully completed the first closing of its Series D financing round of USD 55 million. The proceeds from this financing round will be used to continue advancing the company's clinical and preclinical-stage research and development pipelines, accelerate global clinical development programs, strengthen regulatory and registration efforts in key markets, and further expand the company's research and development capabilities.

Otsuka Pharmaceutical announced that its anti-APRIL monoclonal antibody, sibeprenlimab (brand name: VOYXACT®), has been officially approved by the National Medical Products Administration (NMPA) of China for the treatment of adult patients with primary IgA nephropathy. As the first therapy selectively targeting APRIL (A Proliferation-Inducing Ligand), sibeprenlimab intervenes in disease progression at its source by blocking a key step in the generation of pathogenic IgA.

The development of this sector has three distinct milestones: from 2019 to 2021, it was in an exploratory phase, with only a few small-sample clinical trials conducted in China; from 2022 to 2024, it entered a critical period for regulatory approval, during which multiple companies advanced their efforts simultaneously, yet no product obtained NMPA registration certification; in 2025,H&H Healthcare's K-Clip received approval, marking the official start of the commercialization era and serving as a turning point for the sector's development.

This collaboration aims to discover candidate drugs with clinical differentiation advantages for high-potential therapeutic targets. By applying advanced generative AI models to the early stages of drug development, both teams are poised to comprehensively enhance the quality of candidate molecule design and conduct structural optimization, striving to achieve best-in-class efficacy and ideal safety profiles.

According to reports, PRIMEAI's artificial intelligence modules can achieve gross margins of 70% to 80%, with overall delivery gross margins exceeding 60%. This high-profitability business model precisely aligns with pharmaceutical companies' demands for cost reduction and efficiency improvement. In 2026, the company is projected to achieve revenue exceeding RMB 100 million, with total contract value approaching RMB 160 million, marking the entry of its commercialization into a phase of exponential growth.

Alebund Pharmaceuticals (Jiangsu) Limited, a clinical-stage biotech focused on chronic kidney disease treatments, made its debut on the Hong Kong Stock Exchange June 29, 2026, with its stock jumping more than 95% to HK$44 at press time and valuing the firm at roughly HK$15 billion. The IPO is set to raise HK$1.181 billion, with 34% earmarked for the New Drug Application filing and global Phase 3 multi-center studies of flagship asset AP301, 37% allocated to global Phase 2b trials for AP306 alongside progress on pipeline candidates including AP308 and AP303, and 12% designated for capacity expansion at its Yangzhou manufacturing facility and pre-launch commercial preparations for future approved therapies.

It forms an effective portfolio strategy with Keppra: Keppra, as a broad-spectrum foundational medication, covers a wide patient population with epilepsy and provides stable cash flow; Vimpat, as a next-generation specialized product, targets more segmented treatment scenarios with higher efficacy demands, representing future growth potential. This "cornerstone product + growth product" combination effectively balances current revenue with future opportunities.

If Abbisko Therapeutics successfully advances the compound to the agreed-upon milestone, Eli Lilly will have the right to further develop and commercialize it, with a corresponding total potential consideration of $258 million. If Eli Lilly chooses not to advance the compound, Abbisko Therapeutics will retain the right to further develop and commercialize it.

The innovative drug industry is fiercely competitive, with a scarcity of high-quality, differentiated late-stage pipelines, forcing MNCs to pivot toward early-stage projects. Although China's innovative drug R&D system is characterized by being "fast, cost-effective, and efficient," this does not alter the fundamental principles of drug development: late-stage projects have a higher likelihood of successful commercialization, whereas early-stage projects suffer from lower success rates.

Peripheral Drug-Coated Balloons (Peripheral DCBs) are core consumables for peripheral arterial interventional therapy, suitable for various scenarios such as lower extremity vascular stenosis, in-stent restenosis, and arteriovenous fistula lesions. Compared with traditional stents, peripheral DCBs offer advantages including no foreign body residue post-procedure, lower risk of inflammation, and better long-term prognosis.

GlaxoSmithKline’s (GSK) long-acting FGF21 analog, efimosfermin alfa, has received IND acceptance from China’s Center for Drug Evaluation (CDE), marking a major advancement in MASH therapy with once-monthly dosing. Engineered to overcome the short half-life of native FGF21, efimosfermin alfa demonstrates a triple mechanism—reducing liver fat, combating inflammation, and reversing fibrosis. Phase II data published in The Lancet showed that after 24 weeks, 68% of patients achieved MASH resolution without fibrosis worsening, 89% had ≥30% liver fat reduction, and 32% reached full liver fat normalization. The drug’s efficacy is independent of GLP-1 background therapy. Acquired by GSK for up to $2 billion, efimosfermin alfa is now advancing into global Phase III trials (ZENITH-1/2) with over 1,250 planned enrollments, offering new hope for China’s estimated 200–300 million NAFLD patients, 10–20% of whom may progress to MASH.